Nutex Health H1 2025 revenue $455.8M (+217.5% YoY), net income $3.5M, launches $25M buyback

Nutex Health Inc.

2025-Q3 EPS reported $8.87 revenue$723,578,000

H1 2025 revenue $455.8M (+217.5% YoY); net income $3.5M vs net loss $0.7M in H1 2024.
Diluted EPS $0.55 (H1 2025) vs $(0.15); Adjusted EBITDA $144.4M vs $6.4M YoY.
Q2 2025 revenue $244.0M (+220.7% YoY); net loss $17.7M includes $78.7M non-cash stock-based comp.
Board authorized $25M stock repurchase program on Aug 14, 2025 to offset dilution.
Net cash from operations $78.2M H1; cash balance $96.7M at June 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.